Edition:
United Kingdom

Sonoma Pharmaceuticals Inc (SNOA.OQ)

SNOA.OQ on NASDAQ Stock Exchange Capital Market

4.88USD
15 Dec 2017
Change (% chg)

$0.05 (+1.04%)
Prev Close
$4.83
Open
$4.90
Day's High
$5.05
Day's Low
$4.88
Volume
9,368
Avg. Vol
6,339
52-wk High
$8.18
52-wk Low
$4.17

Latest Key Developments (Source: Significant Developments)

Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Sonoma Pharmaceuticals Inc ::SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS.  Full Article

Sonoma Pharmaceuticals announces FDA approval of expanded indication for Alevicyn
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Sonoma Pharmaceuticals Inc ::Announces FDA approval of expanded indication for Alevicyn to add antimicrobial language.Approved Alevicyn dermal spray, to include antimicrobial language and antimicrobial data against clinically relevant microorganisms​.  Full Article

Sonoma Pharmaceuticals posts Q2 loss $‍0.67/shr from continuing operations​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals reports robust top line growth for second quarter FY 2018 with 61 pct product revenue growth and total revenue of $4.3 million.Q2 revenue $4.3 million versus $2.8 million.Sonoma Pharmaceuticals qtrly loss per share from continuing operations​ $‍0.67.  Full Article

Sonoma Pharmaceuticals receives Brazilian approvals
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Sonoma Pharmaceuticals Inc :Sonoma Pharmaceuticals receives Brazilian approvals to market multiple hypochlorous acid-based dermatology products.Sonoma Pharmaceuticals Inc - ‍is currently seeking to partner with a Brazilian healthcare co relative to licensing newly approved products.Sonoma Pharmaceuticals Inc - ‍issuance of regulatory approvals by Brazilian Ministério Da Saúde for 7 of co's dermatology products​.  Full Article

Oculus Innovative sciences Q1 revenue $3.8 million versus $3.7 million
Thursday, 28 Jul 2016 

Oculus Innovative Sciences Inc : Oculus innovative sciences reports financial results for first quarter of fiscal year 2017 .Q1 revenue $3.8 million versus $3.7 million.  Full Article

Oculus Innovative Sciences says Q4 revenue fell 11 pct to $3.5 mln
Thursday, 16 Jun 2016 

Oculus Innovative Sciences Inc : Net loss for quarter ended March 31, 2016, was $2.9 million, an increase of $1.4 million . Oculus innovative sciences reports financial results for fiscal year 2016 and fourth quarter ending March 31, 2016 .Q4 revenue fell 11 percent to $3.5 million.  Full Article

Oculus Innovative Sciences, Inc says pricing of $3.4 Million Underwritten Public Offering
Friday, 18 Mar 2016 

Oculus Innovative Sciences, Inc:Says pricing of an underwritten public offering of 3,400,000 units, consisting of 3,400,000 shares of common stock.Gross proceeds to Oculus Innovative Sciences from this offering are approximately $3.4 million before deducting the underwriting discount and other estimated offering expenses.Offering is expected to close on or about March 23, 2016, subject to customary closing conditions.  Full Article

BRIEF-Sonoma Pharmaceuticals announces second FDA approval to add antimicrobial language to alevicyn gel products

* SONOMA PHARMACEUTICALS ANNOUNCES SECOND FDA APPROVAL TO ADD ANTIMICROBIAL LANGUAGE TO ALEVICYN™ GEL PRODUCTS FOR MANAGEMENT OF ATOPIC DERMATITIS Source text for Eikon: Further company coverage: